NFATC2

Summary

NFATC2 (nuclear factor of activated T cells 2, HGNC:7776) is a protein-coding gene on chromosome 20q13.2, encoding Nuclear factor of activated T-cells, cytoplasmic 2 (Q13469). Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF.

This gene is a member of the nuclear factor of activated T cells (NFAT) family. The product of this gene is a DNA-binding protein with a REL-homology region (RHR) and an NFAT-homology region (NHR). This protein is present in the cytosol and only translocates to the nucleus upon T cell receptor (TCR) stimulation, where it becomes a member of the nuclear factors of activated T cells transcription complex. This complex plays a central role in inducing gene transcription during the immune response. Alternate transcriptional splice variants encoding different isoforms have been characterized.

Source: NCBI Gene 4773 — RefSeq curated summary.

At a glance

• Gene–disease (curated): lymphoproliferative syndrome (Moderate, GenCC) — +2 more curated relationships
• GWAS associations: 25
• Clinical variants (ClinVar): 147 total — 1 likely-pathogenic
• Phenotypes (HPO): 12
• Cancer driver (intOGen): activating (oncogene-like) across 2 cancer types
• Transcription factor: yes — 98 downstream targets (CollecTRI)
• MANE Select transcript: NM_012340

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7776
Approved symbol	NFATC2
Name	nuclear factor of activated T cells 2
Location	20q13.2
Locus type	gene with protein product
Status	Approved
Aliases	NF-ATP, NFATp, NFAT1
Ensembl gene	ENSG00000101096
Ensembl biotype	protein_coding
OMIM	600490
Entrez	4773

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 retained_intron

ENST00000371564, ENST00000396009, ENST00000414705, ENST00000496054, ENST00000609507, ENST00000609943, ENST00000610033, ENST00000875252

RefSeq mRNA: 8 — MANE Select: NM_012340 NM_001136021, NM_001258292, NM_001258294, NM_001258295, NM_001258296, NM_001258297, NM_012340, NM_173091

CCDS: CCDS13437, CCDS33488, CCDS46614, CCDS68156, CCDS68157

Canonical transcript exons

ENST00000371564 — 11 exons

Exon	Start	End
ENSE00000662707	51435188	51435314
ENSE00000662708	51435706	51435761
ENSE00000662709	51454548	51454688
ENSE00000662710	51473980	51474152
ENSE00000662711	51475458	51475660
ENSE00000662712	51516784	51516955
ENSE00000662713	51523081	51524110
ENSE00001374118	51398643	51398730
ENSE00001455516	51432067	51432756
ENSE00001455518	51542370	51542719
ENSE00003677652	51386963	51391451

Expression profiles

Bgee: expression breadth ubiquitous, 230 present calls, max score 96.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.0061 / max 249.8081, expressed in 1243 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187932	8.8804	868
187934	2.7658	593
187936	0.1264	54
187933	0.1251	65
187935	0.0590	27
187931	0.0495	22

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vena cava	UBERON:0004087	96.62	gold quality
synovial joint	UBERON:0002217	93.56	gold quality
layer of synovial tissue	UBERON:0007616	92.71	gold quality
oviduct epithelium	UBERON:0004804	91.43	gold quality
nipple	UBERON:0002030	90.62	gold quality
buccal mucosa cell	CL:0002336	90.21	gold quality
pylorus	UBERON:0001166	90.03	gold quality
tendon of biceps brachii	UBERON:0008188	89.97	gold quality
cartilage tissue	UBERON:0002418	89.65	gold quality
saphenous vein	UBERON:0007318	89.47	gold quality
upper arm skin	UBERON:0004263	89.28	gold quality
trachea	UBERON:0003126	89.16	gold quality
urethra	UBERON:0000057	88.18	gold quality
trigeminal ganglion	UBERON:0001675	86.71	gold quality
granulocyte	CL:0000094	86.53	gold quality
cardia of stomach	UBERON:0001162	86.13	gold quality
epithelium of mammary gland	UBERON:0003244	86.08	gold quality
mammary duct	UBERON:0001765	85.99	gold quality
mammalian vulva	UBERON:0000997	85.38	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	85.38	gold quality
lymph node	UBERON:0000029	85.18	gold quality
parotid gland	UBERON:0001831	85.17	gold quality
epithelial cell of pancreas	CL:0000083	84.85	silver quality
jejunal mucosa	UBERON:0000399	84.64	gold quality
penis	UBERON:0000989	84.62	gold quality
ileal mucosa	UBERON:0000331	84.08	silver quality
secondary oocyte	CL:0000655	83.68	gold quality
jejunum	UBERON:0002115	83.58	gold quality
trabecular bone tissue	UBERON:0002483	82.71	gold quality
tendon	UBERON:0000043	82.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.02

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

98 targets.

Target	Regulation
ABCA1	Activation
ACP5
APOBEC3G	Activation
APP
ATM
BACE1
CBX3
CCL5	Activation
CCNA2	Unknown
CCR9
CD28
CD34
CD3E
CD3G	Repression
CD4	Activation
CD40
CD40LG	Unknown
CDK4	Repression
CFLAR
CIITA
CREBBP
CSF2	Activation
CTLA4
CX3CR1
CXCL8
EGR3	Unknown
ENPP2	Unknown
ENTPD2	Unknown
FASLG
FGF2

JASPAR motifs

Motif	Name	Family
MA0152.1	NFATC2	NFAT-related factors

JASPAR matrix evidence (PMIDs): PMID:17916232

Upstream regulators (CollecTRI, top): HMGA1, MBD2, NFATC2, NFKB, RUNX2, SP1, SP2, STAT5A, TCF3

miRNA regulators (miRDB)

207 targeting NFATC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-4267	99.96	66.53	2368

Literature-anchored findings (GeneRIF, showing 40)

• Recombinant NFATp binds DNA on its own and cooperatively with AP-1 proteins, activates transcription in vitro, is phosphorylated, can be dephosphorylated by calcineurin, and exhibits regulated association with nuclei in vitro. (PMID:11231878)
• C-terminal one third of DNA binding domain confers different binding specificity of NFATc and NFATp to an NFAT site in the TNF-alpha promoters (PMID:11911478)
• NF-ATc2 induces apoptosis in Burkitt’s lymphoma cells through signaling via the B cell antigen receptor (PMID:12594826)
• Differential responsiveness of cord blood T cells cannot be attributed to differences at the level of NFAT1 expression. (PMID:14657699)
• sumoylation has a dual role in the nuclear localization and transcriptional activation of NFAT1 (PMID:15117942)
• identify a conserved docking site for casein kinase 1 (CK1) in NFAT proteins and show that mutation of this site disrupts NFAT1-CK1 interaction and causes constitutive nuclear localization of NFAT1 (PMID:15121840)
• Nuclear factor of activated T cells balances angiogenesis activation and inhibition. (PMID:15184502)
• role in activating interleukin-5 receptor (PMID:15271374)
• These results suggest a novel and unexpected role for members of the NFAT transcription factor family in the hematopoietic system. (PMID:15292278)
• Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms (PMID:15347678)
• the nuclear factor of activated T cell-dependent transactivation pathway has a role in viral protein A238L inhibition of cyclooxygenase-2 expression (PMID:15471864)
• Expression of NFATc1 and NFATc2 wild type protein or the active catalytic subunit of calcineurin transactivates COX-2 promoter activity, whereas a dominant negative mutant of NFAT inhibited COX-2 induction in colon carcinoma cell lines. (PMID:15632146)
• CAML is an important signal transducer for the actions of Ang II in regulating the calcineurin-NFAT pathway and the interaction of CAML with ATRAP may mediate the Ang II actions in vascular physiology (PMID:15668245)
• NFAT and SRF may interact to cooperatively regulate smooth muscle cell-specific gene expression and NFAT may have a role in the phenotypic maintenance of smooth muscle (PMID:15857835)
• alpha6beta4 integrin potentiates autotaxin expression through the upregulation and activation of NFAT1. (PMID:15897878)
• NFATc2 activity is regulated by caspase-3 (PMID:16455648)
• NFKB and NFAT regulate BLyS expression via at least one NFKB and 2 NFAT BLYS promoter binding sites. Constitutive activation of NFKB and BLyS in NHL-B cells forms a positive feedback loop associated with lymphoma cell survival and proliferation (PMID:16497967)
• NFAT promotes breast cancer cell invasion through the induction of COX-2 and the synthesis of prostaglandins (PMID:16505480)
• results indicate that HIV-1 Tat interacts with NFAT, affecting its cooperation with AP-1, without altering independent binding of these transcription factors to DNA (PMID:16690925)
• Studies with NFAT1-sufficient and -deficient double-transgenic bone marrow chimeric mice demonstrate that the transcription factor NFAT1 is involved in B cell anergy. (PMID:16849457)
• Constitutive expression of NFAT1/NFATc2 in transgenic mice controls bone resorption in vivo by stimulating differentiation and functioning of osteoclasts but not their survival. (PMID:16888000)
• In Wiskott-Aldrich CD8+ T cells, a block in cytokine production correlates with reduced nuclear levels of both NFAT-1 and NFAT-2. (PMID:17082665)
• Ral is activated upon BCR stimulation and mediates BCR-controlled activation of AP-1 and NFAT transcription factors. (PMID:17237388)
• the amount of NF-ATc2 bound to the promoters of CD154 (CD40L) and IL-2 genes in SLE; although high NF-ATc2 levels translated into higher CD154 transcription in SLE, IL-2 transcription was decreased (PMID:17237447)
• MAP3K8 and PRKCZ cooperate in the regulation of the transcriptional activity of NFATC2 through the phosphorylation of its amino-terminal domain. (PMID:17398070)
• NFAT1 could explain low FOXP3 expression and diminished Treg frequency in aplastic anemia. (PMID:17463169)
• NFAT1 mediates proinflammatory gene expression in response to mechanotransduction (PMID:17584983)
• Changes in AP-1 composition and the level of participating NFAT proteins can differentially influence cytokine gene expression, resulting in biological consequences for the modulation and dynamics of the immune response. (PMID:17588603)
• the WIP-WASP complex plays an important role in WASP stabilization and NFAT activation (PMID:17711847)
• NFAT1 is a critical regulator of CTLA-4 gene expression that binds to the CTLA-4 promoter in human T cells. (PMID:17785820)
• O-GlcNAc modification might be required for nuclear translocation of the transcription factors NFkappaB and NFAT (PMID:17882263)
• The promoter/enhancer activity of the NFAT-binding site in the TNF-alpha gene was up-regulated by NFATc2 but not by NFATc1, whereas both NFATs associated similarly with this region. (PMID:18097033)
• study found that Homer2 and Homer3 are negative regulators of T cell activation; this is achieved through binding of nuclear factor of activated T cells (NFAT) and by competing with calcineurin (PMID:18218901)
• Unexpected coupling of PML with NFAT reveals a novel mechanism underlying the diverse physiological functions of promyelocytic leukemia. (PMID:18246125)
• accumulation of HIF-1alpha in activated mast cells requires up-regulation of HIF1A gene transcription and depends on the calcineurin-NFAT signaling pathway (PMID:18641302)
• NFAT and MyoD cooperation regulates myogenin expression and myogenesis (PMID:18676376)
• NFATc2 has a role in colitis by controlling mucosal T cell activation in an IL-6-dependent manner (PMID:18710929)
• Normalization of the constitutive VEGFR2 signaling in hemangioma endothelial cells with soluble VEGFR1 or antibodies that neutralize VEGF or stimulate beta1 integrin (PMID:18931684)
• our results establish crucial roles for enhancer element CNS-9, and NFAT1 and IRF4 that bind to it, for IL-10 expression in differential T helper subsets. (PMID:18962896)
• Children with type 1 diabetes show decreased insudtion of MFATc2 in T cells. (PMID:18973208)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	nfatc2a	ENSDARG00000100927
mus_musculus	Nfatc2	ENSMUSG00000027544
rattus_norvegicus	Nfatc2	ENSRNOG00000012175

Paralogs (4): NFATC3 (ENSG00000072736), NFATC4 (ENSG00000100968), NFAT5 (ENSG00000102908), NFATC1 (ENSG00000131196)

Protein

Protein identifiers

Nuclear factor of activated T-cells, cytoplasmic 2 — Q13469 (reviewed: Q13469)

Alternative names: NFAT pre-existing subunit, T-cell transcription factor NFAT1

All UniProt accessions (1): Q13469

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF. Promotes invasive migration through the activation of GPC6 expression and WNT5A signaling pathway. Is involved in the negative regulation of chondrogenesis. Recruited by AKAP5 to ORAI1 pore-forming subunit of CRAC channels in Ca(2+) signaling microdomains where store-operated Ca(2+) influx is coupled to calmodulin and calcineurin signaling and activation of NFAT-dependent transcriptional responses.

Subunit / interactions. Member of the multicomponent NFATC transcription complex that consists of at least two components, a pre-existing cytoplasmic component NFATC2 and an inducible nuclear component NFATC1. Other members such as NFATC4, NFATC3 or members of the activating protein-1 family, MAF, GATA4 and Cbp/p300 can also bind the complex. The phosphorylated form specifically interacts with XPO1; which mediates nuclear export. NFATC proteins bind to DNA as monomers. Interacts with NFATC2IP. Interacts with FOXP3. Interacts with TBX21 (‘Thr-303’ phosphorylated form). Interacts with KAT2A. Interacts with HOMER2 and HOMER3; this interaction competes with calcineurin/PPP3CA-binding and hence prevents NFATC2 dephosphorylation and activation. Interacts with protein phosphatase PPP3CA/calcineurin A. Interacts with AKAP5 (via leucine zipper domain); this is required for NFATC2/NFAT1 recruitment to CRAC channels.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in thymus, spleen, heart, testis, brain, placenta, muscle and pancreas. Isoform 1 is highly expressed in the small intestine, heart, testis, prostate, thymus, placenta and thyroid. Isoform 3 is highly expressed in stomach, uterus, placenta, trachea and thyroid.

Post-translational modifications. In resting cells, phosphorylated by NFATC-kinase on at least 18 sites in the 99-363 region. Upon cell stimulation, all these sites except Ser-243 are dephosphorylated by calcineurin. Dephosphorylation induces a conformational change that simultaneously exposes an NLS and masks an NES, which results in nuclear localization. Simultaneously, Ser-53 or Ser-56 is phosphorylated; which is required for full transcriptional activity. Ubiquitinated in endothelial cells by RNF213 downstream of the non-canonical Wnt signaling pathway, leading to its degradation by the proteasome.

Disease relevance. Joint contractures, osteochondromas, and B-cell lymphoma (JCOSL) [MIM:620232] An autosomal recessive disorder characterized by musculoskeletal and hematopoietic issues. Affected individuals develop painless fixed joint contractures in early childhood, have osteochondromas, osteopenia, and can develop B-cell lymphomas. The disease may be caused by variants affecting the gene represented in this entry.

Domain organisation. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors. Rel Similarity Domain (RSD) allows DNA-binding and cooperative interactions with AP1 factors.

Induction. Inducibly expressed in T-lymphocytes upon activation of the T-cell receptor (TCR) complex. Induced after co-addition of phorbol 12-myristate 13-acetate (PMA) and ionomycin.

Isoforms (5)

UniProt ID	Names	Canonical?
Q13469-1	1, C, NFATc2_IB_IIL	yes
Q13469-2	2, B
Q13469-3	3, NFATc2_IA_IIL
Q13469-4	4
Q13469-5	5

RefSeq proteins (8): NP_001129493, NP_001245221, NP_001245223, NP_001245224, NP_001245225, NP_001245226, NP_036472, NP_775114 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002909	IPT_dom	Domain
IPR008366	NFAT	Family
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR011539	RHD_DNA_bind_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR014756	Ig_E-set	Homologous_superfamily
IPR032397	RHD_dimer	Domain
IPR037059	RHD_DNA_bind_dom_sf	Homologous_superfamily

Pfam: PF00554, PF16179

UniProt features (90 total): modified residue 30, strand 28, region of interest 7, short sequence motif 4, helix 4, repeat 3, compositionally biased region 3, splice variant 3, turn 3, chain 1, domain 1, DNA-binding region 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

12 structures.

PDB	Method	Resolution (Å)
8R3F	X-RAY DIFFRACTION	1.55
8R07	X-RAY DIFFRACTION	1.74
1P7H	X-RAY DIFFRACTION	2.6
1A02	X-RAY DIFFRACTION	2.7
2AS5	X-RAY DIFFRACTION	2.7
8OW4	X-RAY DIFFRACTION	2.75
3QRF	X-RAY DIFFRACTION	2.8
9VRQ	X-RAY DIFFRACTION	2.8
1OWR	X-RAY DIFFRACTION	3
2O93	X-RAY DIFFRACTION	3.05
1PZU	X-RAY DIFFRACTION	3.1
1S9K	X-RAY DIFFRACTION	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13469-F1	57.69	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (30): 23, 99, 107, 110, 148, 168, 171, 172, 174, 175, 177, 180, 213, 217, 221, 236, 243, 255, 268, 274 …

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-2025928	Calcineurin activates NFAT
R-HSA-2871809	FCERI mediated Ca+2 mobilization
R-HSA-5607763	CLEC7A (Dectin-1) induces NFAT activation
R-HSA-8877330	RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)

MSigDB gene sets: 404 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, BIOCARTA_FMLP_PATHWAY, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_CARTILAGE_DEVELOPMENT, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_B_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_SMOOTH_MUSCLE_CELL_DIFFERENTIATION, KEGG_MAPK_SIGNALING_PATHWAY, GOBP_SMOOTH_MUSCLE_CELL_DIFFERENTIATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION

GO Biological Process (20): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), DNA damage response (GO:0006974), response to xenobiotic stimulus (GO:0009410), positive regulation of gene expression (GO:0010628), myotube cell development (GO:0014904), cell migration (GO:0016477), positive regulation of B cell proliferation (GO:0030890), calcineurin-NFAT signaling cascade (GO:0033173), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), B cell receptor signaling pathway (GO:0050853), cartilage development (GO:0051216), cellular response to calcium ion (GO:0071277), lncRNA transcription (GO:0140742), positive regulation of myoblast fusion (GO:1901741), negative regulation of vascular associated smooth muscle cell differentiation (GO:1905064), negative regulation of transcription by RNA polymerase II (GO:0000122), gene expression (GO:0010467)

GO Molecular Function (14): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), phosphatase binding (GO:0019902), molecular adaptor activity (GO:0060090), 14-3-3 protein binding (GO:0071889), sequence-specific double-stranded DNA binding (GO:1990837), transcription cis-regulatory region binding (GO:0000976), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (8): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737), cytosol (GO:0005829), transcription factor AP-1 complex (GO:0035976), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Downstream signaling events of B Cell Receptor (BCR)	1
Fc epsilon receptor (FCERI) signaling	1
CLEC7A (Dectin-1) signaling	1
Transcriptional regulation by RUNX1	1
Differentiation of T cells	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	4
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
cellular anatomical structure	4
regulation of DNA-templated transcription	3
transcription by RNA polymerase II	3
regulation of transcription by RNA polymerase II	3
binding	3
regulation of gene expression	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
protein-containing complex	2
regulation of RNA biosynthetic process	1
cellular response to stress	1
response to chemical	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
myotube differentiation	1
striated muscle cell development	1
cell motility	1
regulation of B cell proliferation	1
B cell proliferation	1
positive regulation of lymphocyte proliferation	1
positive regulation of B cell activation	1
calcineurin-mediated signaling	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
antigen receptor-mediated signaling pathway	1
skeletal system development	1
animal organ development	1
connective tissue development	1
response to calcium ion	1
cellular response to metal ion	1
myoblast fusion	1
positive regulation of syncytium formation by plasma membrane fusion	1
regulation of myoblast fusion	1
vascular associated smooth muscle cell differentiation	1
negative regulation of smooth muscle cell differentiation	1
regulation of vascular associated smooth muscle cell differentiation	1
negative regulation of DNA-templated transcription	1
macromolecule biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1

Protein interactions and networks

STRING

2242 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NFATC2	JUN	P05412	942
NFATC2	FOS	P01100	937
NFATC2	CREB1	P16220	930
NFATC2	SMAD3	P84022	925
NFATC2	RELA	Q04206	879
NFATC2	FOXP3	Q9BZS1	843
NFATC2	CALM1	P02593	778
NFATC2	CALML3	P27482	778
NFATC2	CALML5	Q9NZT1	778
NFATC2	CALML6	Q8TD86	772
NFATC2	CALML4	Q96GE6	772
NFATC2	PPP3R1	P06705	759
NFATC2	IL2	P01585	758
NFATC2	NFATC1	O95644	747
NFATC2	HDAC1	Q13547	743

IntAct

48 interactions, top by confidence:

A	B	Type	Score
FOS	JUN	psi-mi:“MI:2364”(proximity)	0.980
JUN	NFATC1	psi-mi:“MI:0914”(association)	0.610
VRK2	NFATC2	psi-mi:“MI:0217”(phosphorylation reaction)	0.610
VRK2	NFATC2	psi-mi:“MI:0915”(physical association)	0.610
NFATC2	VRK2	psi-mi:“MI:0915”(physical association)	0.610
VRK2	NFATC2	psi-mi:“MI:0407”(direct interaction)	0.610
LRRK2	PSMD11	psi-mi:“MI:0914”(association)	0.600
	FOXP2	psi-mi:“MI:0407”(direct interaction)	0.590
	NFATC2	psi-mi:“MI:0914”(association)	0.590
	FOXP2	psi-mi:“MI:0914”(association)	0.590
	FOXP2	psi-mi:“MI:0915”(physical association)	0.590
PPP3CA	NFATC2	psi-mi:“MI:0407”(direct interaction)	0.560
NFATC2	LRRK2	psi-mi:“MI:0915”(physical association)	0.560
IL2	NFATC2	psi-mi:“MI:0914”(association)	0.530
NFATC2	IL2	psi-mi:“MI:0914”(association)	0.530
	NFATC2	psi-mi:“MI:0915”(physical association)	0.500
	NFATC2	psi-mi:“MI:0914”(association)	0.500
NFATC2	CREB1	psi-mi:“MI:0915”(physical association)	0.500
NFATC2	NFATC2	psi-mi:“MI:0407”(direct interaction)	0.440
NFATC2		psi-mi:“MI:0915”(physical association)	0.400
	NFATC2	psi-mi:“MI:0915”(physical association)	0.400
NFATC2	USP22	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (234): HCVgp1 (Reconstituted Complex), NFATC2 (Reconstituted Complex), NFATC2 (Affinity Capture-MS), NFATC2 (Affinity Capture-MS), IKZF1 (Affinity Capture-Western), JUN (Affinity Capture-Western), RPTOR (Affinity Capture-Western), CREB1 (Affinity Capture-Western), EP300 (Affinity Capture-Western), FOS (Affinity Capture-Western), CHEK1 (Affinity Capture-Western), SCAI (Affinity Capture-Western), IKZF2 (Affinity Capture-Western), GSK3B (Affinity Capture-Western), RUNX1 (Affinity Capture-Western)

ESM2 similar proteins: A0A0G2JTY4, A2VD01, A5PMU4, A8E4V2, D2HNW6, E1BEQ5, O54972, O95644, P16236, P59281, P70365, P97305, Q12968, Q13191, Q13469, Q13905, Q15788, Q1LY51, Q2VPU4, Q3LRZ1, Q3TTA7, Q3U182, Q4PJW2, Q4VCS5, Q60591, Q61122, Q66IV1, Q68FF7, Q6DFR2, Q6GQL0, Q6NYU6, Q6ZNC4, Q80TM6, Q80VG1, Q8HWS3, Q8IXK0, Q8IY63, Q8K4S7, Q8N228, Q8VHG2

Diamond homologs: A0A0G2JTY4, D3Z9H7, D3ZGB1, O77638, O88942, O94916, O95644, P97305, P98201, Q12968, Q13469, Q14934, Q60591, Q8K120, Q9WV30

SIGNOR signaling

91 interactions.

A	Effect	B	Mechanism
NFATC2	up-regulates	MEF2A	binding
NFATC2	up-regulates	MEF2D	binding
MAPK8	down-regulates	NFATC2	phosphorylation
MAPK9	down-regulates	NFATC2	phosphorylation
PPP3CA	up-regulates	NFATC2	dephosphorylation
GSK3B	down-regulates	NFATC2	phosphorylation
VRK2	up-regulates	NFATC2	phosphorylation
PPP3CB	up-regulates	NFATC2	dephosphorylation
PPP3CC	up-regulates	NFATC2	dephosphorylation
NFATC2	“up-regulates quantity by expression”	MYOG	“transcriptional regulation”
PPP3CB	“up-regulates activity”	NFATC2	dephosphorylation
PPP3CC	“up-regulates activity”	NFATC2	dephosphorylation

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 2 cancer types — PAAD, READ.

Clinical variants and AI predictions

ClinVar

147 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	116
Likely benign	8
Benign	6

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1693111	NM_012340.5(NFATC2):c.*71T>G	Likely pathogenic

SpliceAI

2871 predictions. Top by Δscore:

Variant	Effect	Δscore
20:51435182:CCTTA:C	donor_loss	1.0000
20:51435183:CTTAC:C	donor_loss	1.0000
20:51435184:TTAC:T	donor_loss	1.0000
20:51435185:TA:T	donor_loss	1.0000
20:51435186:ACCTG:A	donor_loss	1.0000
20:51435187:CCTGG:C	donor_gain	1.0000
20:51435311:TGTT:T	acceptor_gain	1.0000
20:51435688:G:C	donor_gain	1.0000
20:51435704:A:AC	donor_gain	1.0000
20:51435705:C:CC	donor_gain	1.0000
20:51435705:CGGG:C	donor_gain	1.0000
20:51454684:CTGGG:C	acceptor_gain	1.0000
20:51454685:TGGG:T	acceptor_gain	1.0000
20:51454688:GC:G	acceptor_loss	1.0000
20:51454689:C:CC	acceptor_gain	1.0000
20:51454690:T:G	acceptor_loss	1.0000
20:51473979:CAGCA:C	donor_gain	1.0000
20:51475456:A:AC	donor_gain	1.0000
20:51475457:C:CC	donor_gain	1.0000
20:51475656:TGGAG:T	acceptor_gain	1.0000
20:51475657:GGAG:G	acceptor_gain	1.0000
20:51475658:GAG:G	acceptor_gain	1.0000
20:51475659:AG:A	acceptor_gain	1.0000
20:51475659:AGCT:A	acceptor_loss	1.0000
20:51475661:C:CC	acceptor_gain	1.0000
20:51475662:T:C	acceptor_loss	1.0000
20:51475664:G:GC	acceptor_gain	1.0000
20:51516778:CCATA:C	donor_loss	1.0000
20:51516779:CATAC:C	donor_loss	1.0000
20:51516780:ATAC:A	donor_loss	1.0000

AlphaMissense

5976 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:51435197:A:C	Y675D	1.000
20:51435202:A:G	F673S	1.000
20:51435216:A:C	S668R	1.000
20:51435216:A:T	S668R	1.000
20:51435218:T:G	S668R	1.000
20:51435241:A:T	V660D	1.000
20:51435301:A:T	V640D	1.000
20:51435747:A:G	W622R	1.000
20:51435747:A:T	W622R	1.000
20:51454565:A:G	F611S	1.000
20:51454571:A:T	V609D	1.000
20:51454589:A:G	F603S	1.000
20:51454598:C:A	G600V	1.000
20:51454598:C:T	G600E	1.000
20:51454599:C:A	G600W	1.000
20:51454599:C:G	G600R	1.000
20:51454599:C:T	G600R	1.000
20:51454604:A:G	L598P	1.000
20:51454604:A:T	L598H	1.000
20:51454658:A:T	V580D	1.000
20:51454664:G:C	P578R	1.000
20:51454664:G:T	P578H	1.000
20:51454684:C:A	Q571H	1.000
20:51454684:C:G	Q571H	1.000
20:51473981:G:C	C569W	1.000
20:51473982:C:T	C569Y	1.000
20:51473983:A:G	C569R	1.000
20:51473988:A:T	I567N	1.000
20:51473997:G:A	S564F	1.000
20:51473997:G:T	S564Y	1.000

dbSNP variants (sampled 300 via entrez): RS1000004679 (20:51400380 C>A), RS1000014784 (20:51563201 T>C), RS1000027112 (20:51404557 A>G), RS1000052732 (20:51525369 A>G), RS1000081362 (20:51433067 C>T), RS1000094108 (20:51486484 C>G,T), RS1000101324 (20:51553880 C>G), RS1000135593 (20:51443449 T>G), RS1000135999 (20:51436181 G>A), RS1000172720 (20:51409535 C>T), RS1000188095 (20:51447098 T>A,G), RS1000228980 (20:51447368 G>A), RS1000239730 (20:51518435 C>T), RS1000241461 (20:51400087 A>C), RS1000244849 (20:51453534 T>C)

Disease associations

OMIM: gene MIM:600490 | disease phenotypes: MIM:115200, MIM:620232

GenCC curated gene-disease

Disease	Classification	Inheritance
lymphoproliferative syndrome	Moderate	Autosomal recessive
joint contractures, osteochondromas, and B-cell lymphoma	Limited	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Disputed	AD

Mondo (3): dilated cardiomyopathy 1A (MONDO:0007269), joint contractures, osteochondromas, and B-cell lymphoma (MONDO:0859369), lymphoproliferative syndrome (MONDO:0016537)

Orphanet (1): Familial dilated cardiomyopathy with conduction defect due to LMNA mutation (Orphanet:300751)

HPO phenotypes

12 total (12 of 12 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0002953	Vertebral compression fracture
HP:0003273	Hip contracture
HP:0004349	Reduced bone mineral density
HP:0006380	Knee flexion contracture
HP:0006466	Ankle flexion contracture
HP:0008445	Cervical spinal canal stenosis
HP:0008940	Generalized lymphadenopathy
HP:0011463	Childhood onset
HP:0012191	B-cell lymphoma
HP:0030080	Burkitt lymphoma
HP:0030431	Osteochondroma

GWAS associations

25 associations (top):

Study	Trait	p-value
GCST002083_34	Self-reported allergy	7.000000e-09
GCST002114_4	Molar-incisor hypomineralization	5.000000e-06
GCST002337_24	Amyotrophic lateral sclerosis (sporadic)	5.000000e-06
GCST002682_15	Tourette’s syndrome or obsessive-compulsive disorder	8.000000e-06
GCST002843_17	Sitting height ratio	8.000000e-10
GCST002915_2	Asparaginase hypersensitivity in acute lymphoblastic leukemia	4.000000e-08
GCST004600_113	Eosinophil percentage of white cells	7.000000e-09
GCST004624_72	Sum eosinophil basophil counts	4.000000e-09
GCST004993_1	White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)	1.000000e-07
GCST005038_54	Allergic disease (asthma, hay fever or eczema)	1.000000e-12
GCST006409_28	Allergic rhinitis	5.000000e-08
GCST006624_125	Systolic blood pressure	4.000000e-17
GCST007847_93	Type 2 diabetes	2.000000e-09
GCST007928_10	Medication use (diuretics)	2.000000e-10
GCST007929_85	Medication use (calcium channel blockers)	1.000000e-08
GCST007930_27	Medication use (agents acting on the renin-angiotensin system)	4.000000e-08
GCST008152_62	Weight	2.000000e-06
GCST008163_272	Height	1.000000e-06
GCST009674_2	Urinary uric acid excretion	4.000000e-06
GCST010042_143	Asthma	3.000000e-09
GCST010118_79	Type 2 diabetes	7.000000e-10
GCST90002381_254	Eosinophil count	6.000000e-12
GCST90002382_533	Eosinophil percentage of white cells	2.000000e-14
GCST90002388_583	Lymphocyte count	4.000000e-09
GCST90020024_806	A body shape index	5.000000e-08

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0005321	molar-incisor hypomineralization
EFO:0007118	sitting height ratio
EFO:0004881	asparaginase hypersensitivity
EFO:0007991	eosinophil percentage of leukocytes
EFO:0004842	eosinophil count
EFO:0005090	basophil count
EFO:0005674	white matter microstructure measurement
EFO:0006335	systolic blood pressure
EFO:0009928	Diuretic use measurement
EFO:0009930	Calcium channel blocker use measurement
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0004338	body weight
EFO:0004761	uric acid measurement
EFO:0004587	lymphocyte count
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008232	Lymphoproliferative Disorders	C15.604.515; C20.683.515

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs6021191	Toxicity	3	asparaginase	Acute lymphoblastic leukemia

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3787186	NFATC2		0.00	0
rs6021191	NFATC2	3	3.00	1	asparaginase
rs6123048	NFATC2		0.00	0

CTD chemical–gene interactions

72 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, increases methylation	4
Calcimycin	increases reaction, decreases phosphorylation, increases activity, decreases reaction, affects cotreatment (+1 more)	3
Tetradecanoylphorbol Acetate	affects binding, increases expression, affects cotreatment, increases activity, affects localization (+3 more)	3
bisphenol A	affects cotreatment, decreases methylation, increases expression, affects reaction, decreases expression	2
arsenite	decreases reaction, increases methylation, affects binding	2
sodium arsenite	affects methylation, increases expression	2
Arsenic	affects methylation, increases expression	2
Benzo(a)pyrene	decreases methylation, affects methylation	2
Cisplatin	affects cotreatment, decreases expression	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
fisetin	decreases reaction, increases activity	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
hydroquinone	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
N-(4-hydroxyphenyl)arachidonylamide	decreases activity	1
entinostat	increases expression	1
bisperoxovanadium	affects localization, affects binding, increases reaction, affects reaction, increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Rosiglitazone	affects response to substance	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7YG	Abcam Raji NFATC2 KO	Cancer cell line	Male
CVCL_B8LG	Abcam HCT 116 NFATC2 KO	Cancer cell line	Male
CVCL_B8ZG	Abcam MCF-7 NFATC2 KO	Cancer cell line	Female
CVCL_B9NM	Abcam A-549 NFATC2 KO	Cancer cell line	Male
CVCL_E0IY	Ubigene HeLa NFATC2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

106 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00033475	PHASE3	COMPLETED	Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
NCT00053053	PHASE3	COMPLETED	Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
NCT00058331	PHASE3	COMPLETED	Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
NCT00070382	PHASE3	COMPLETED	Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
NCT00516503	PHASE3	COMPLETED	Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00661999	PHASE3	COMPLETED	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
NCT00666211	PHASE3	COMPLETED	Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT00719563	PHASE3	COMPLETED	American Ginseng in Treating Patients With Fatigue Caused by Cancer
NCT00750009	PHASE3	COMPLETED	Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
NCT03394365	PHASE3	RECRUITING	A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT05431179	PHASE3	WITHDRAWN	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00001379	PHASE2	COMPLETED	Treatment and Natural History Study of Lymphomatoid Granulomatosis
NCT00001438	PHASE2	COMPLETED	A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
NCT00066469	PHASE2	COMPLETED	Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
NCT00092222	PHASE2	ACTIVE_NOT_RECRUITING	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
NCT00255749	PHASE2	COMPLETED	Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00387530	PHASE2	WITHDRAWN	Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
NCT00416624	PHASE2	COMPLETED	Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
NCT00436618	PHASE2	COMPLETED	Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT00621036	PHASE2	WITHDRAWN	Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
NCT00869323	PHASE2	TERMINATED	Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
NCT00992732	PHASE2	TERMINATED	Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
NCT01116232	PHASE2	TERMINATED	Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
NCT01118013	PHASE2	TERMINATED	Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
NCT02579967	PHASE2	RECRUITING	Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
NCT02861417	PHASE2	ACTIVE_NOT_RECRUITING	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT03258567	PHASE2	RECRUITING	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
NCT03373019	PHASE2	UNKNOWN	Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03663933	PHASE2	ACTIVE_NOT_RECRUITING	Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
NCT03744676	PHASE2	COMPLETED	A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
NCT03922724	PHASE2	RECRUITING	Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
NCT04339777	PHASE2	RECRUITING	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
NCT04463615	PHASE2	COMPLETED	Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
NCT04554914	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04858256	PHASE2	RECRUITING	Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT04883437	PHASE2	RECRUITING	Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
NCT00002153	PHASE1	COMPLETED	Topical Use of 4,4’-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi’s Sarcoma and Lymphoproliferative Disorders
NCT00013689	PHASE1	COMPLETED	Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
NCT00028418	PHASE1	COMPLETED	Clofarabine in Chronic Lymphocytic Leukemia
NCT00058604	PHASE1	COMPLETED	Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).